CollabRx, Inc. (NASDAQ: CLRX) said it has closed its previously announced underwritten public offering of 913,500 shares of its common stock, offered at a public offering price of USD2.00 per share.
Gross proceeds to CollabRx from this offering were USD1,827,000 before deducting the underwriting discount and other estimated offering expenses payable by CollabRx.
CollabRx said it anticipates using the net proceeds from the offering for general corporate purposes, including development of their products and services, general and administrative expenses and working capital.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
CollabRx is a leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world´s knowledge on genomics-based medicine with specific insights from the nation´s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.